Skip to content
Screener

Vir Biotechnology, Inc. VIR Q3 2025 earnings

Reported November 5, 2025 · After market close

Revenue$240.0KMiss by $19.7M
EPS-$1.17Miss by $0.47
Revenue estimate$19.9M
EPS estimate-$0.70

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$865.1K
EPS estimate-$0.74

Financials

Q3 2025

Income statement

See full
Revenue$240.0K-89.9%
Operating income-$173.4M+25.0%
Net income-$163.1M+23.7%
EPS (diluted)-$1.17+25.0%

Balance sheet

See full
Cash & equivalents$179.3M-32.2%
Total debt$100.2M-11.2%
Total equity$796.1M-35.8%
Total assets$1.0B-32.0%

Cash flow

See full
Operating cash flow-$167.6M+2.3%
CapEx$317.0K-88.5%
Free cash flow-$167.9M+3.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$793.21M-22.3%
Enterprise value$714.13M-17.8%
P/S47×+34.1×

Profitability

See full
Operating margin-3,253.6%-4,733pp
Net margin-2,963.5%-4,215pp
FCF margin-2,728.5%-3,807pp

Returns & leverage

See full
Return on equity-49.1%+25.4pp
Debt / equity0.1×0.0×
Current ratio7.3×-1.7×

Segments

By segment

See full
Reportable Segment$240.0K-89.9%

By product

See full
Grant revenue$305.0K—

FAQ

When did Vir Biotechnology, Inc. report Q3 2025 earnings?
Vir Biotechnology, Inc. (VIR) reported Q3 2025 earnings on November 5, 2025 after market close.
What were Vir Biotechnology, Inc.'s Q3 2025 revenue and EPS?
Vir Biotechnology, Inc. reported revenue of $240.0K and eps of $-1.17 for Q3 2025.
Did Vir Biotechnology, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $19.9M by $19.7M. EPS missed the consensus estimate of $-0.70 by $0.47.
How did Vir Biotechnology, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 89.9% from $2.4M a year earlier and eps grew 25.0% from $-1.56.
Where can I find Vir Biotechnology, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-049561) and the 10-Q periodic report (0001628280-25-049694) directly on SEC EDGAR. The filing index links above go to sec.gov.